TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Participated in Study 20110233 (NCT01588496) or another qualifying evolocumab parent protocol and have a diagnosis of familial hypercholesterolemia.~OR~* Have a diagnosis of familial hypercholesterolemia AND~* Males and females ≥ 12 to ≤ 80 years of age~* Stable low-fat diet and lipid-lowering therapies for at least 4 weeks~* Low-density lipoprotein cholesterol (LDL-C) \>= 130 mg/dl (3.4 mmol/L) for subjects without diagnosed coronary heart disease (CHD)/CHD risk equivalent OR LDL-C \>= 100 mg/dl (2.6 mmol/L) for subjects with diagnosed CHD or CHD risk equivalent OR apheresis patients have no LDL-C entry requirement~* Fasting triglycerides ≤ 400 mg/dL(4.5 mmol/L)~* Body weight of \> 40 kg or greater at screening for subjects less than 18 years of age~Exclusion Criteria:~* New York Heart Failure Association (NYHA) class III or IV or last known left ventricular ejection fraction \< 30%~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of screening~* Planned cardiac surgery or revascularization~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* An epilepsy patient with generalized tonic-clonic seizures that are classifiable according to the ILAE classification of epileptic seizures (Epilepsia, 1981)~* A patient on a stable dose of 1 or 2 anti-epileptic drugs for the last 4 weeks (potassium bromide and sodium bromide for the last 12 weeks) prior to and during the combined baseline period~Exclusion Criteria:~* Presence of any sign (clinical or imaging procedures) suggesting a progressive brain lesion/disease, in particular, progressive disorder with epileptic seizures~* Diagnosis of Lennox-Gastaut Syndrome~* Confirmed focal epilepsy based on clinical signs (seizure types), with consistent electroencephalogram and magnetic resonance imagining features~* A history of convulsive or non-convulsive status epilepticus while taking concomitant anti-epileptic drugs for the last 3 months prior to Visit 1

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for 28 weeks
- Levetiracetam (Type: EXPERIMENTAL): Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Were vaccinated with LBVH0101 or Hiberix™ three times in LG-VHCL002 study~* Healthy male and female infants at the age of 12 to 15 months from birth~* The infants and their parents/legally acceptable representative could comply with all of the scheduled visits in the study~* The parents/legally acceptable representative signed the written consent form.~Exclusion Criteria:~* Subject had been vaccinated with 4th shot of Haemophilus influenzae type b~* Subject is scheduled to be administered with any vaccine other than those specified in the protocol as allowed according to the Standard Immunization Schedule, between the 4th vaccination and Completion Visit~* Subject had suffered from any infectious disease caused by Haemophilus influenzae type b~* Subject has fever of ≥ 37.5°C (axillary temperature) at the day of vaccination~* There is a clear or suspected immune function disorder~* Systemic corticosteroid (prednisolone or equivalent \> 0.5 mg/kg/day) was administered for more than 14 days within 30 days prior to administration of the test vaccine or any systemic immunosuppressant was used

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: f

Study Arms:
- LBVH0101 (Type: EXPERIMENTAL): None
- Hiberix (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Treatment of Cannabis Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females age 18-65 with cannabis dependence~* Meets DSM-IV-TR criteria for Cannabis Dependence~* Smoked marijuana at least once a week in the 90 days prior to study participation~* Willing to attend 12 weekly study visits and 1 follow-up visit~Exclusion Criteria:~* Currently meets DSM-IV-TR criteria for dependence on illicit substances other than cannabis~* Significant medical disorders that will increase potential risk or interfere with study participation~* Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control~* Treatment with an investigational drug in the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin (Type: EXPERIMENTAL): 1200 mg/daily of Gabapentin
- Placebo (Type: PLACEBO_COMPARATOR): 1200mg/d of Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxytyrosol and Vitamin E in Pediatric NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Liver biopsy consistent with diagnosis of NASH (liver biopsy performed in 3-6 months before enrollment)~* Hyperechogenicity of liver at ultrasound examination~* ALT levels range between normal and \< 10 UNL~* INR \< 1.3~* Albumin \> 3 gr/dl.~* Total bilirubin \< 2.5 mg/dl~* normal renal function~* normal cells blood count~* exclusion of other causes of chronic hepatopathies in children~* Written informed consent to participate in the Protocol by their parents or legal guardians of patients~Exclusion Criteria:~* alcohols or drugs abuse~* use of drugs known to induce steatosis or to affect body weight or carbohydrate metabolism~* autoimmune liver diseases, Wilson's disease, alpha-1-antitripsin deficiency, metabolic liver disease~* every clinical or psychiatric diseases interfering with experimentation according to investigator's evaluation~* finding of active liver disease due to other causes

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- TREATED GROUP (Type: EXPERIMENTAL): This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
- PLACEBO GROUP (Type: PLACEBO_COMPARATOR): This group will treated with 2 identical placebo pills daily given orally for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Historical diagnosis of type 2 diabetes mellitus for at least 6 months and less than 10 years before Screening~* HbA1c \<10% at Screening for subjects who do not require washout of existing OAD or \<9% at Screening for subjects who do require washout from existing OAD~* Body mass index in range 28 kg/m2 to40 kg/m2~Exclusion Criteria:~* History of pancreatitis or current ongoing symptomatic biliary disease or pancreatitis~* History of significant gastrointestinal surgery,~* History of significant cardiovascular disease~* History of a seizure disorder~* Documented hypertension or hypotension~* Use of oral antidiabetic agents, except for metformin, within 14 days before investigational product administration.~* Current hepatic disease or abnormal liver function tests~* Positive test result for hepatitis B, hepatitis C, or human immunodeficiency virus infection 1 or 2~* History of regular alcohol consumption (exceeding 7 drinks/week for women or 14 drinks/week for men)~* Female subject is pregnant (confirmed by laboratory testing), lactating, or less than 6 weeks postpartum~* Known allergy to any GLP-1 analog or excipients of albiglutide, Baker's yeast, or insulin~* History of type 1 diabetes,~* Prior exposure to GLP-1 agents, including albiglutide~* Blood donation over 500 mL within 8 weeks before Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- albiglutide (Type: ACTIVE_COMPARATOR): single dose of albiglutide
- placebo (Type: PLACEBO_COMPARATOR): single dose of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Objective diagnosis of colorectal cancer;~* Elective laparoscopic surgery for colorectal cancer~* Whatever the stage of cancer~* Antithrombotic prophylaxis with LMWH administered for 7±2 days after surgery~Exclusion Criteria:~* Age \< 18 years~* Surgery for non-cancer disease~* Duration of surgery \< 45 min~* Conversion to open surgery~* Other indication for anticoagulant therapy~* Known cerebral metastases~* Kidney or liver failure~* Known hemorrhagic diathesis or high risk for bleeding~* History of intracerebral bleeding or neurosurgery within 6 months~* History of heparin induced thrombocytopenia~* Pregnancy or lactation~* Refusal of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
- Placebo (Type: PLACEBO_COMPARATOR): Orally administered, OD for 3 weeks (extended prophylaxis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Essential hypertension.~* Currently taking between one and three antihypertensive medications at a stable dose for at least four weeks before Visit 1 of preceding trial 502.480.~* Blood pressure not adequately controlled on existing treatment before entry to preceding trial 502.480 (inadequate control defined as seated DBP \>= 95 mmHg on one current antihypertensive medication or DBP \>= 90 mmHg on two or more current antihypertensive medications).~* Failure to respond to six weeks run-in treatment with T80/H12.5 in preceding trial 502.480. (Failure to respond defined as seated DBP \>= 90 mmHg.)~* Willing and able to provide written informed consent.~Exclusion criteria:~* Women of child-bearing potential NOT practising acceptable means of birth control, positive serum pregnancy test, breastfeeding.~* Known or suspected secondary hypertension.~* Clinically significant change in ECG reported as adverse event in preceding trial 502.480.~* Any medical condition developing in preceding trial 502.480 that could be worsened by telmisartan/HCTZ (80/25).~* Discontinuation from preceding 502.480 trial for adverse event or any other reason.~* Mean SBP \>= 200 mmHg.~* Severe hepatic or renal impairment.~* Bilateral renal artery stenosis (or in a solitary kidney), post-renal transplant or only one functioning kidney.~* Clinically relevant hypokalaemia or hyperkalaemia.~* Uncorrected volume or sodium depletion, primary aldosteronism.~* Hereditary fructose intolerance.~* Previous symptoms of angioedema after ACE inhibitors or angiotensin-II receptor antagonists.~* Drug or alcohol dependency within the six months prior to entry to 502.480. concurrent participation in another clinical trial or any investigational therapy.~* Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.~* Allergic hypersensitivity to any component of the formulations under investigation.~* Concomitant therapy with lithium, cholestyramine or colestipol resins.~* Non-compliance with study medication (less than 80% or more than 120%) during the preceding 502.480 trial.~* Any other clinical condition which, in the opinion of the investigator, would not allow safe administration of telmisartan or hydrochlorothiazide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole Once-monthly in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Patients will be recruited among those who complete treatment with aripiprazole in Study 14724A / NCT01795547.~Inclusion Criteria:~* The patient is judged to potentially benefit from 24-week treatment with aripiprazole once-monthly according to the clinical opinion of the investigator.~* The patient agrees to protocol-defined use of effective contraception.~Exclusion Criteria:~* The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14724A / NCT01795547.~* The patient has a clinically significant unstable illness diagnosed during Study 14724A / NCT01795547.~* The patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).~* The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability or efficacy, or interfere with the conduct or interpretation of the study.~* The patient has one or more clinical laboratory test values outside the reference range, based on the blood or urine samples taken during the conduct of Study 14724A / NCT01795547 that are, in the investigator's opinion, of potential risk to the patient's safety.~* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole once-monthly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Current use of an artificial tear at least twice daily, for at least three months prior to Day 1, on average~* Ability/agreement to wear habitual correction (glasses) during study period~Exclusion Criteria:~* Known allergy or sensitivity to the study product(s) or its components~* Anticipate contact lens wear during the study, or subject has worn contact lenses in the last six months~* Chronic use of systemic medications which may affect a dry eye condition~* Active ocular allergy or infection~* Use of Restasis® or other topical cyclosporine products within 3 months prior to Day 1~* Current use of any topical ophthalmic medications, have used within 2 weeks prior to Day 1, or are likely to use during study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glycerin and Polysorbate 80 based artificial tear (Type: ACTIVE_COMPARATOR): Glycerin and Polysorbate 80 based artificial tear
- Artificial Tears Formulation 1 (Type: EXPERIMENTAL): Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
- Artificial Tears Formulation 2 (Type: EXPERIMENTAL): Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Chinese subjects aged 18-65 years (including 65) at screening.~* Subjects meeting the ICD-10 (Classification of Mental and Behavioral Disorders) criteria for schizophrenia (F20.X).~* Subjects who are in acute phase of schizophrenia and are appropriate to receive intramuscular medication for at least 3 days~Exclusion Criteria:~* History of clinically significant physical illness especially myocardial infarction, non compensatory heart failure etc.~* Subjects receiving an investigational agent in the previous 3 months prior to screening.~* Use of antipsychotic agents within 12 hours or parenteral benzodiazepines within 4 hours prior to randomization and during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intramuscular ziprasidone (Type: EXPERIMENTAL): None
- Intramuscular haloperidol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: (Gastrografin Use in Small Bowel Obstruction Caused by Adherences)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\>18 years)~* History of previous abdominal surgical procedures~* Clinical and radiological evidence of adhesive small intestine obstruction without signs of strangulation and peritonism~* ASA I-III patients~* Informed consent~Exclusion Criteria:~* Suspicion of strangulation~* Actual presence or high suspicion of intra-abdominal malignancy~* Suspicion or history of peritoneal carcinomatosis~* active inflammatory bowel disease~* Positive history of radiotherapy on the abdominal region~* Obstructed hernias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GG (Type: EXPERIMENTAL): None
- TT (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete